Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karim Lebtahi"'
Autor:
Luc, Dasnois, Karim, Lebtahi, Jorge, Abarca-Quinones, Nathalie, Havaux, Samuel, Dupont, Vincent, Dubois, André, Trouet
Publikováno v:
Journal of experimental therapeuticsoncology. 4(2)
The ETAP concept (Extracellularly Tumor-Activated Prodrug) is a new approach developed to overcome the lack of selectivity and the side effects responsible for the limited efficacy of chemotherapeutic agents. CPI-0004Na, a doxorubicin (Dox) prototype
Autor:
Vincent, Dubois, Luc, Dasnois, Karim, Lebtahi, Françoise, Collot, Nathalie, Heylen, Nathalie, Havaux, Anne-Marie, Fernandez, Thomas J, Lobl, Cecilia, Oliyai, Matthew, Nieder, Dan, Shochat, Geoffrey T, Yarranton, André, Trouet
Publikováno v:
Cancer research. 62(8)
The search for cancer therapies that are more selective for tumor cells and spare normal sensitive cells has been very active for at least 20 years. The extracellularly tumor-activated peptidic prodrug of doxorubicin (Dox) CPI-0004Na (N-succinyl-beta
Autor:
Luc Dasnois, André Trouet, E R Lewis, Karim Lebtahi, K. Van Derpoorten, T J Lobl, Vincent Dubois, Anne-Marie Fernandez, D Shochat, S Gangwar, Cecilia Oliyai
Publikováno v:
Journal of medicinal chemistry. 44(22)
Intravenous administration of N-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin (4) induces an acute toxic reaction, killing animals in a few minutes. This results from its positive charge at physiological pH combined with its propensity to form
Autor:
Dasnois, Luc1 dasnois@bani.ucl.ac.be, Lebtahi, Karim1, Abarca-Quinones, Jorge1, Havaux, Nathalie1, Dupont, Samuel1, Dubois, Vincent1, Trouet, André1
Publikováno v:
Journal of Experimental Therapeutics & Oncology. 2004, Vol. 4 Issue 2, p169-171. 3p. 1 Chart, 1 Graph.